LRHC

Executive Summary

Your 12-month 8-K record contains two Item 4.02 non-reliance filings (accession 0001213900-26-050950 on 2026-05-01 and 0001213900-26-047626 on 2026-04-24) filed three business days apart, which is the single most consequential disclosure-risk signal in the window. Compounding this, you have two separate Item 3.01 listing-deficiency-type filings (0001213900-26-046409 on 2026-04-22 and 0001213900-26-068260 on 2026-06-12), plus a third 3.01 reference on 2026-05-22, indicating an unresolved or recurring exchange compliance dialogue. You also disclosed unregistered equity issuances under Item 3.02 on 2026-05-27 and 2026-06-10, which outside readers will pair with the restatement signal and read as a dilution-plus-restatement pattern. Two of your 8-Ks (0001213900-26-046409 and 0001213900-26-060667) include Item 3.01 content that our parser flagged as also referenced under Item 8.01, which sophisticated readers sometimes characterize as compliance news being softened by placement under “Other Events.” The audit is based on 13 8-K filings only; no 10-K, 10-Q, S-1, S-3, or DEF 14A was in the provided dataset, so this brief is disclosure-cadence focused and cannot speak to MD&A, going-concern, or auditor-change language. Overall posture is ELEVATED and the trajectory is worsening driven principally by the April–May restatement cluster. Recommend the audit committee be walked through the 4.02 sequence and the 3.01 cadence before the next earnings call.

Overall Risk Posture

The combination of two Item 4.02 non-reliance filings within a single week, recurring Item 3.01 listing/compliance notices, and Item 3.02 unregistered issuances in the same quarter elevates the disclosure-language risk profile above what a typical small-cap would present. Nothing in the 8-K set is fatal on its own, but the clustering is what outside readers optimize for.

Trajectory: worsening — The 4.02 pair (0001213900-26-047626 on 2026-04-24 and 0001213900-26-050950 on 2026-05-01) is followed by additional 3.01 activity on 2026-05-22 (0001213900-26-060667) and 2026-06-12 (0001213900-26-068260), suggesting the compliance and restatement threads did not close within the window.

Signal Breakdown

Pre-Call Brief

The following questions an analyst is most likely to raise on the next earnings call, with framing suggestions. Each is rooted in a specific filing in the audit window.

Board / Audit Committee Brief

Audit committee implications

The audit committee should be briefed on the sequencing of the two Item 4.02 filings and whether the second filing represents an expansion of scope or a distinct issue. Because the 4.02 sequence overlaps with three Item 3.01 listing notices and two Item 3.02 unregistered issuances, the committee should confirm that legal and disclosure counsel reviewed the ordering of restatement disclosure relative to the financing counterparties. The committee should also confirm the status of any amended periodic reports and whether the auditor has concurred on the non-reliance conclusion in writing. Finally, the committee should have documented visibility into whether the exchange dialogue underlying the 3.01 filings remains open.

Documentation recommendations

Board minutes should reflect a specific discussion of the 4.02 sequence, including the date the audit committee concluded non-reliance and the basis for that conclusion. The risk register should carry an entry for continued listing compliance with the specific rule cited in each 3.01 notice and the cure deadline. A separate register entry should track the 3.02 issuances with counterparty categories, exemption relied upon, and any registration rights that follow. Documentation should also capture the rationale for bundling Item 1.01, 3.02, and 5.03 in the 2026-05-27 filing so that the record is clear if questioned later. Where possible, retain the internal timeline showing that 4.02 disclosure preceded the subsequent unregistered issuances.

What Was NOT Found

The provided dataset contained no 10-K, 10-Q, S-1, S-3, DEF 14A, or 8-K Item 5.02 (officer or director departure) filings, so we did not surface signals related to going-concern language, MD&A liquidity disclosures, auditor changes, officer departure clustering, or proxy contest activity. We also did not observe any Item 4.01 (change in certifying accountant) filing in the window, which is a notable negative given the 4.02 activity, since auditor changes often accompany restatements. No ATM program disclosures, shelf takedowns, or named sales agents were parsed from the 8-K set. These absences may reflect the dataset scope rather than the absence of such filings; the IRO should confirm.